Virology The goals of the Virology Program are to continue to identify the mechanisms through which human tumor viruses induce cancer and to use these findings to develop translational studies that target these processes. The major programmatic areas are Immunity, Pathogenesis, Vims:Cell Interactions, and AIDS-associated Cancers: A.) The Immunity group has focused on the development of effective new vaccines for viral infection and cancer, viral vectors for gene delivery, and the identification of the effects of viral infection on innate immunity and inflammation. Alphavimses and corona viruses have powerful effects on innate immunity and their mechanisms to impair this response are under study. Additionally, the effects of EBV and KSHV on interferon regulatory factors and toll-like receptors are under study. B.) The Pathogenesis group analyzes human tumor specimens to identify the viral effects on cell growth and expression and have developed transgenic mice to model the malignancies associated with these viruses. C.) The VimsiCell Interaction's studies have revealed effects of EBV and KSHV on the ubiquitin pathway including the identification of virally encoded deubiquitinases, and have analyzed viral activation of the PI3kinase/Akt/pcatenin and NFKB pathways. D.) The study of AIDS-associated virally induced cancers is expanding and three NCI supplemental grants for the study of AIDS-associated cancers have been recently funded. Experimental translational studies have been initiated to treat AIDS-associated lymphomas and characterize oral HPV infection. Three of the investigators that study human herpesvimses are funded through a Virology Program Project grant with projects that are based on newly developed technologies that are available through the Lineberger Cancer Center shared resources, including the Proteomics Core and Next Generation Sequencing. New members of the Program study viral infections in humanized mouse models, HCV, and human papilloma virus (HPV). The etiologic contributions of the human tumor viruses, EBV, KSH'V, HCV, and HPV will be further analyzed through the study of clinical samples, in vitro transformation systems, and animal models. The future plans for the Program include recruitment of additional investigators in virally-associated cancers and the expansion of specific anti-viral and immuno-therapies for these cancers with specific focus on experimental therapeutics for AIDS malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594131
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$151,662
Indirect Cost
$66,182
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications